

Electronic supplementary information

Heterobimetallic Ru(II)/Fe(II) complexes as potent anticancer agents against breast cancer cells, inducing apoptosis through multiple targets

Adriana Pereira Mundim Guedes^{a*}, Francylli Mello-Andrade^{b,c}, Wanessa Carvalho Pires^b, Maria Alice Montes de Sousa^d, Paula Francinete Faustino da Silva^b, Mariana S. de Camargo^a, Hendryk Gemeiner^e, Amauri A. Menegário^e, Clever Gomes Cardoso^f, Paulo Roberto de Melo Reis^d, Elisângela de Paula Silveira-Lacerda^b, Alzir A. Batista^{a*}








Fig. S1 Permeation across Caco-2 cells, represented by concentration after permeation of complexes 1-3 through the Caco-2 cell membrane per time, quantified by ICP-MS. Each value represents the mean derived from at least three individual experiments in triplicate (mean \pm SD).

(A)



(B)



(C)




Fig. S2 Stability Study. ^{31}P NMR (^1H) spectra of complexes **1** (A), **2** (B) and **3** (C) in culture medium / DMSO solution (20/80%(v/v)).




Fig. S3 Effect of HSA on the cytotoxicity of complex 1 (A), 2 (B) and 3 (C) against breast tumor cell (MDA-MB-231) after 48h. MDA-MB-231 cells were treated with complex 1 at 0.3 μ M (A), complex 2 at 0.8 μ M (B) and complex 3 at 0.5 μ M (C) pre-incubated with HSA at 1:1, 1:3, 1:5 and 1:10 complex-to-protein molar ratio. Control indicated cells without treatment.




Fig. S4 Effects of complexes 1, 2 and 3 at different concentrations on MDA-MB-231 colony formation after 48 h treatment and quantification of colony area %.




Fig. S5 Percentage of apoptosis and necrosis after treatment with $1/2$ IC₅₀ and IC₅₀ of the complexes 1-3 by double staining with HO/PI. Data show the means \pm SD of experiments performed in triplicate. Significant differences from the control are indicated by * $p < 0.05$; ** $p < 0.01$ and *** $p < 0.001$.




Fig. S6 Morphology of MDA-MB-231 cells treated with complex 1 (0.15 and 0.30 μM) by 0, 24 and 48 h.




Fig. S7 Morphology of MDA-MB-231 cells treated with complex 2 (0.40 and 0.80 μM) by 0, 24 and 48 h.




Fig. S8 Morphology of MDA-MB-231 cells treated with complex 3 (0.25 and 0.50 μM) by 0, 24 and 48 h.